OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Navigating New Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

home / peer-exchange / navigating-new-treatment-options-in-relapsed-refractory-diffuse-large-b-cell-lymphoma

A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.

Experts on DLBCL

EP. 1: Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Expert on DLBCL

EP. 2: Front-Line Treatment of DLBCL

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Expert on DLBCL

EP. 3: Relapsed and Refractory Diffuse Large B-Cell Lymphoma

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

Expert on DLBCL

EP. 4: Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

By Kami J. Maddocks, MD
Jason Westin, MD
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
  • David Miklos, MD, Stanford University
February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Expert on DLBCL

EP. 5: CAR-T Therapy

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Expert on DLBCL

EP. 6: CAR-T Therapies in R/R DLBCL

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

Experts on DLBCL

EP. 7: Safety With CAR-T Therapies in R/R DLBCL

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

Expert on DLBCL

EP. 8: Real-World Data With CAR-T Therapies in R/R DLBCL

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Expert on DLBCL

EP. 9: Monoclonal Antibodies for Treatment of R/R DLBCL

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Expert on DLBCL

EP. 10: Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Richard T. Maziarz, MD
  • Grzegorz S. Nowakowski, MD
February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Expert on DLBCL

EP. 11: Concluding Thoughts on the DLBCL Treatment Landscape

By Kami J. Maddocks, MD
Jason Westin, MD
  • David Miklos, MD, Stanford University
  • Grzegorz S. Nowakowski, MD
  • Richard T. Maziarz, MD
February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Latest Conference Coverage

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact